Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ammonia N-13 is a radioactive diagnostic agent used in positron emission tomography (PET) imaging, primarily for the evaluation of myocardial perfusion in patients with suspected or existing coronary artery disease. The active ingredient, [13N] ammonia, is a small molecule radiopharmaceutical labeled with the radioisotope nitrogen N 13. After intravenous administration, it is rapidly extracted by myocardial cells and metabolized to N‑13 glutamine, resulting in intracellular retention that enables high-quality PET visualization of the myocardium. Ammonia N‑13 may also be used investigationally for brain tumor differentiation and has shown potential utility in liver and prostate cancer diagnosis[1][2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ammonia n-13.